Literature DB >> 9448318

Insulin-like growth factor I restores motor coordination in a rat model of cerebellar ataxia.

A M Fernandez1, A G de la Vega, I Torres-Aleman.   

Abstract

We tested the potential of insulin-like growth factor I (IGF-I) to induce functional recovery in an animal model of cerebellar ataxia because this motor impairment is accompanied in humans and rodents by distinct changes in several components of the IGF-I trophic system. Rats rendered ataxic by deafferentation of the cerebellar cortex with 3-acetylpyridine recovered motor function after IGF-I was administered, as determined by behavioral and electrophysiological tests. When treated with IGF-I, inferior olive neurons, the targets of the neurotoxin, were rescued to various degrees (from 92 to 27% of surviving neurons), depending on the time that treatment with IGF-I was initiated. Furthermore, full recovery was obtained regardless of the route by which the trophic factor was administered (intraventricular or subcutaneous) even in rats with severe neuronal loss. These results suggest that human ataxia could be treated with IGF-I by a simple procedure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9448318      PMCID: PMC18736          DOI: 10.1073/pnas.95.3.1253

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

Review 1.  Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations.

Authors:  W H Daughaday; P Rotwein
Journal:  Endocr Rev       Date:  1989-02       Impact factor: 19.871

2.  Transient IGF-I gene expression during the maturation of functionally related central projection neurons.

Authors:  C A Bondy
Journal:  J Neurosci       Date:  1991-11       Impact factor: 6.167

Review 3.  Reciprocal trophic interactions in the adult climbing fibre-Purkinje cell system.

Authors:  F Rossi; P Strata
Journal:  Prog Neurobiol       Date:  1995 Nov-Dec       Impact factor: 11.685

4.  Calbindin-D 28k immunoreactivity in the cerebellum of spinocerebellar degeneration.

Authors:  K Ishikawa; H Mizusawa; T Fujita; N Ohkoshi; M Doi; Y Komatsuzaki; H Iwamoto; T Ogata; S Shoji
Journal:  J Neurol Sci       Date:  1995-04       Impact factor: 3.181

5.  Regulation of neuronal survival by the serine-threonine protein kinase Akt.

Authors:  H Dudek; S R Datta; T F Franke; M J Birnbaum; R Yao; G M Cooper; R A Segal; D R Kaplan; M E Greenberg
Journal:  Science       Date:  1997-01-31       Impact factor: 47.728

6.  Localisation of insulin-like growth factor-I (IGF-I) immunoreactivity in the olivocerebellar system of developing and adult rats.

Authors:  R M Sherrard; N A Richardson; V R Sara
Journal:  Brain Res Dev Brain Res       Date:  1997-01-02

Review 7.  The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies.

Authors:  B W Festoff; S X Yang; J Vaught; C Bryan; J Y Ma
Journal:  J Neurol Sci       Date:  1995-05       Impact factor: 3.181

8.  Insulin-like growth factor-1 mRNA is increased in deafferented hippocampus: spatiotemporal correspondence of a trophic event with axon sprouting.

Authors:  K M Guthrie; T Nguyen; C M Gall
Journal:  J Comp Neurol       Date:  1995-01-30       Impact factor: 3.215

9.  The insulin-like growth factor I system in cerebellar degeneration.

Authors:  I Torres-Aleman; V Barrios; A Lledo; J Berciano
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

10.  The insulin-like growth factor I system in the rat cerebellum: developmental regulation and role in neuronal survival and differentiation.

Authors:  I Torres-Aleman; S Pons; M A Arévalo
Journal:  J Neurosci Res       Date:  1994-10-01       Impact factor: 4.164

View more
  36 in total

1.  Cerebellar Ataxia.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

2.  Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease.

Authors:  J Garcia de Yebenes; J Yebenes; M A Mena
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

3.  Therapeutic potential of IGF-I on hippocampal neurogenesis and function during aging.

Authors:  Gustavo R Morel; Micaela López León; Maia Uriarte; Paula C Reggiani; Rodolfo G Goya
Journal:  Neurogenesis (Austin)       Date:  2016-12-20

4.  Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise.

Authors:  Catharine H Duman; Lee Schlesinger; Rosemarie Terwilliger; David S Russell; Samuel S Newton; Ronald S Duman
Journal:  Behav Brain Res       Date:  2008-11-14       Impact factor: 3.332

5.  Long-term in vivo time-lapse imaging of synapse development and plasticity in the cerebellum.

Authors:  Naoko Nishiyama; Jeremy Colonna; Elise Shen; Jennifer Carrillo; Hiroshi Nishiyama
Journal:  J Neurophysiol       Date:  2013-10-16       Impact factor: 2.714

Review 6.  Agile delivery of protein therapeutics to CNS.

Authors:  Xiang Yi; Devika S Manickam; Anna Brynskikh; Alexander V Kabanov
Journal:  J Control Release       Date:  2014-06-21       Impact factor: 9.776

Review 7.  Neurotrophic factors for the investigation and treatment of movement disorders.

Authors:  Justo Garcia De Yébenes; Marina Sánchez; Maria Angeles Mena
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 8.  Exercise and brain health--implications for multiple sclerosis: Part 1--neuronal growth factors.

Authors:  Lesley J White; Vanessa Castellano
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

Review 9.  Growth factors as mediators of exercise actions on the brain.

Authors:  M Llorens-Martín; I Torres-Alemán; José L Trejo
Journal:  Neuromolecular Med       Date:  2008-02-20       Impact factor: 3.843

Review 10.  Brain repair and neuroprotection by serum insulin-like growth factor I.

Authors:  Eva Carro; Jose Luis Trejo; Angel Núñez; Ignacio Torres-Aleman
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.